Delcath Systems Stock Forum

$Delcath Systems (DCTH.US)$
Clinical Data: Delcath's Melanoma Treatment Achieves 175% Better Survival Than Standard Care

$Delcath Systems (DCTH.US)$
Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy

$Delcath Systems (DCTH.US)$ why always fall

$Delcath Systems (DCTH.US)$
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH) announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients. The study, conducted by researchers at Moffitt Cancer Center, compared Delcath's HEPZATO KIT™ to immunotherapy and other liver-directed therapies. Key findings include:
1. Overall Survival (OS): Median OS ...

$Delcath Systems (DCTH.US)$ Reuters· 1 min ago1min
Delcath Systems, Inc. Announces Promising Results From Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

$Delcath Systems (DCTH.US)$
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems (Nasdaq: DCTH) announced promising results from an independent study on its CHEMOSAT® Hepatic Delivery System for liver tumors. The study, conducted at the University Hospital of Leipzig, Germany, evaluated 33 patients with various cancers, including uveal melanoma and cholangiocarcinoma. Key findings include:
- A 91% diseas...

$Delcath Systems (DCTH.US)$ Delcath Systems Q1 2024 GAAP EPS $(0.45) Beats $(0.47) Estimate, Sales $3.139M Beat $2.187M Estimate

$Delcath Systems (DCTH.US)$ Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...